Crossmark

Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study

Crossref DOI link: https://doi.org/10.1186/s13075-018-1653-5

Published Online: 2018-07-27

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kampylafka, Eleni

d’Oliveira, Isabelle

Linz, Christina

Lerchen, Veronika

Stemmler, Fabian

Simon, David

Englbrecht, Matthias

Sticherling, Michael

Rech, Jürgen

Kleyer, Arnd

Schett, Georg

Hueber, Axel J. https://orcid.org/0000-0001-6454-1234
License Information

Text and Data Mining valid from 2018-07-27
More Information

Article History

Received: 9 April 2018

Accepted: 27 June 2018

First Online: 27 July 2018

Ethics approval and consent to participate

: In the PSARTROS study (ClinicalTrials.gov Identifier: NCT02483234), all patients provided written informed consent, and institutional review board/ethics committee (Ethik-Kommission der Friedrich-Alexander-Universität Erlangen-Nürnberg) approved the protocol (EC 63_15Az; IRB 2355/01).

: Not applicable.

: The authors declare that they have no competing interests.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Document is current

Any future updates will be listed below